Personalized medicine: boon or budget-buster?
While the development of personalized or molecular medicine is a laudable goal, there remain multiple barriers to its implementation. For example, little is known about the functions of noncoding regions of DNA, as well as the interplay of drug response, environmental factors, and the patient's genetic profile. In addition, there is a constant influx of new information on genetic factors such as epigenetic variation that could further complicate the development of medications based on the genetic profile, as well as the cost of profiling. However, assuming that clinically relevant genetic factors will be discovered and that drugs can be developed based on the molecular changes induced by those genetic factors, I suggest that the costs involved may substantially exceed the savings brought about by abandoning our current "one drug fits all" approach. While there is no doubt that our current approach is inefficient and expensive, remarkably little attention has been paid to the potential costs of molecular medicine. Given the current economic crisis, the time is ripe for a debate on this issue.
Tardive Dyskinesia Assessment Clinic, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA. charles.dean@med.va.gov
Charles E
CE
Dean
D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D023281:Genomics; D017048:Health Care Costs; D006801:Humans; D010597:Pharmacogenetics / Q000191:economics*; D012959:Socioeconomic Factors
D014150:Antipsychotic Agents